The post-translational modification of histones plays an important role in chromatin regulation, a process that insures the fidelity of gene expression and other DNA transactions. Of the enzymes that mediate post-translation modification, the histone acetyltransferase (HAT) and histone deacetylase (HDAC) proteins that add and remove acetyl groups to and from target lysine residues within histones, respectively, have been the most extensively studied at both the functional and structural levels. Not surprisingly, the aberrant activity of several of these enzymes have been implicated in human diseases such as cancer and metabolic disorders, thus making them important drug targets. Significant mechanistic insights into the function of HATs and HDACs have come from the X-ray crystal structures of these enzymes both alone and in liganded complexes, along with associated enzymatic and biochemical studies. In this review, we will discuss what we have learned from the structures and related biochemistry of HATs and HDACs and the implications of these findings for the design of protein effectors to regulate gene expression and treat disease.
Introduction
DNA within the eucaryotic nucleus is compacted through its association with two copies each of the highly basic histone proteins H2A, H2B, H3 and H4 to form nucleosome core particles (Luger et al., 1997 ) that assemble into a dynamic structure known as chromatin (Woodcock, 2006) . The appropriate regulation of chromatin orchestrates several nuclear processes such as DNA transcription, replication, repair, mitosis and apoptosis. The proteins, or associated protein complexes, that regulate chromatin activity fall into at least three different groups; ATP-dependant chromatin remodeling proteins that mobilize the histone proteins within chromatin (Varga-Weisz and Becker, 2006) ; histone chaperone proteins that assemble, disassemble or replace variant histones within chromatin (Loyola and Almouzni, 2004) ; and post-translational modification enzymes that add or remove functional groups to or from the histone proteins (Nightingale et al., 2006) .
The post-translational modifications of histones involve the addition or removal of acetyl, methyl or phosphate groups as well as the reversible transfer of the ubiquitin and sumo proteins. Of the enzymes that carry out post-translational modifications of histones, the proteins that mediate acetyl-transfer onto lysine side chains within the N-terminal histone tails are the most well-studied at both the functional and structural levels (Marmorstein and Roth, 2001a; Marmorstein, 2001b) . The acetylation of histones is carried out by a group of enzymes known as histone acetyl transferases (HATs) and histone deacetylases (HDACs) catalyse the reverse reaction.
The opposing activity of HATs and HDACs tightly regulate gene expression and are roughly correlated with gene activation and repression/silencing, respectively (Brownell and Allis, 1996; Mizzen and Allis, 1998) . Considering the important role that HATs and HDACs play in gene regulation, it has not come as a surprise that alterations in HAT and HDAC activity have been correlated with human diseases. For example, chromosomal translocations involving the monocytic leukemia zinc finger protein (MOZ) and p300/CBP HATs are associated with acute myeloid leukemias and p300/CBP have properties of tumor suppressor proteins (Muraoka et al., 1996; Giles et al., 1998; Chaffanet et al., 2000; Timmermann, 2001 ). In addition, class I/II HDACs have emerged as attractive targets for cancer therapy, as HDAC inhibitors have been found to have potent and specific anticancer activities in preclinical studies (Kelly et al., 2002 (Kelly et al., , 2003 Marks and Jiang, 2005; Bolden et al., 2006) . Finally, the class III HDACs, or sirtuins, have been implicated in diverse biological processes including physiology, metabolism and longevity (Haigis and Guarente, 2006) . Consistent with this regulation, sirtuin activators related to the polyphenol resveratrol have been shown to suppress age-associated diseases such as type II diabetes, obesity and cancer (Wood et al., 2004a, b; Kobayashi et al., 2005; Parker et al., 2005; Anekonda and Reddy, 2006; Baur et al., 2006) .
The pivotal transcriptional role played by the enzymes that catalyse acetyl-transfer, and their association with human diseases as described above has motivated detailed structural and mechanistic studies on their mode of action. In this review, we will summarize what has been learned from the structure of HATs and HDACs together with the associated biochemistry with a particular focus on the implications of these studies for understanding catalytic mechanism and for designing small molecule effectors that target these enzymes for the treatment of human diseases such as cancers.
Overview of nuclear HATs
Nuclear or A-type HAT proteins, to distinguish them from the cytoplasmic B-type HATs, can be grouped into at least three families, Gcn5/PCAF (for its founding member yeast Gcn5 and its ortholog in human, PCAF), MYST (for the founding members MOZ, Ybf2/Sas3, Sas2 and Tip60) and p300/CBP (for the two human paralogs p300 and CBP) (Sterner and Berger, 2000b; Marmorstein, 2001a) . Although other nuclear HAT families have been identified, such as the steroid receptor coactivators (ACTR/AIB1, SRC1), TAF250, ATF-2, their HAT activities have not been studied in detail, so they will not be discussed here. Yeast HAT1 was the first identified B-type HAT and it is discussed in another article in this issue of Oncogene (Parthun, 2007 ). An unusual feature of the nuclear HAT subfamilies is that although they employ a common acetyl (Ac)-CoA cofactor and acetyl-lysine substrate and generate the same reaction products, CoA and deacetylated lysine, they show significant sequence divergence that is believed to be correlated with their distinct substrate specificities and biological activities. Gcn5 and PCAF belong to the GNAT family (Gcn5-related N-acetyltransferase) that contains three conserved sequence motifs (A, B and D) that are shared with other acetyltransferases, including serotonin acetyltransferase and spermidine acetyltransferase (Neuwald and Landsman, 1997) . Some of the other GNAT members contain another conserved C motif. The MYST proteins contain sequence homology to the GNAT proteins only in motif A, and the p300/CBP family has no detectable sequence conservation with either the Gcn5/PCAF or MYST HATs. Several HATs within the Gcn5/PCAF and MYST family have been shown to exist in multisubunit complexes in vivo and at least one activity of these associated HAT subunits appears to be to target the HATs to nucleosomes, as the recombinant Gcn5 and Esa1 HAT proteins strongly prefers free histones over nucleosomes (Sterner and Berger, 2000a; Marmorstein and Roth, 2001b) . Some HATs such as PCAF and p300/CBP have also been shown to target non-histone transcription factors such as p53 and MyoD for acetylation (Glozak et al., 2005; Zhang and Dent, 2005) .
Structure of nuclear HATs
The structure of HAT domains from several members of the Gcn5/PCAF family has been determined by X-ray crystallography and nuclear magnetic resonance, both alone and in complex with substrates (Clements et al., 1999; Lin et al., 1999; Rojas et al., 1999; Trievel et al., 1999; Yan et al., 2000 Yan et al., , 2002 Poux et al., 2002; Poux and Marmorstein, 2003) . These structures reveal that the A, B and D regions of the GNAT proteins form a central core that is structurally homologous to other GNAT proteins and mediates conserved Ac-CoA interactions ( Figure 1a) . The Gcn5/PCAF HAT domains also contain flanking N-and C-terminal domains that show structural divergence to other GNAT proteins. Together, the core and N-and C-terminal flanking regions of the Gcn5/PCAF HAT domain form a pronounced cleft over the core region and flanked by the N-and C-terminal regions that forms the binding site for the acetyl-lysine-bearing histone substrate ( Figure 1a ). Aside from acetyl-lysine contacts that are mediated by the HAT core region, nearly all of the other histone contacts are mediated by the flanking N-and C-terminal regions of the Gcn5/PCAF HAT domain implicating these regions for substrate specificity.
The X-ray crystal structure of the Esa1 (Yan et al., 2000) member of the MYST HAT family bound to CoA reveals a structurally superimposable core domain and CoA interactions with Gcn5/PCAF, despite the very limited sequence conservation between these HATs (Figure 1b) . In contrast, the N-and C-terminal regions of the Esa1 HAT domain are structurally divergent from the corresponding regions of the Gcn5/PCAF HAT domain. Since the flanking N-and C-terminal regions of Gcn5/PCAF play an important role in substrate specificity, it is interesting to speculate that this divergent region of Esa1 plays a similar role, although there is no direct evidence for this.
Although a structure of the HAT domain of p300/ CBP has not yet been reported, biochemical information indicates that it is structurally distinct from the Gcn5/ PCAF and MYST HATs. In particular, it was reported that the p300 HAT domain contains two proteaseresistant domains connected by a long protease-sensitive loop . Moreover, the authors demonstrate that this loop is autoinhibitory in its hypoacetylated form, but undergoes autoacetylation for HAT activation suggesting some allosteric regulation of p300 HAT activation similar to how protein kinases are activated by phosphorylation of their activation loops. Based on the structural comparisons between the Gcn5/PCAF and MYST HATs, we speculate that the p300/CBP HATs may have a structurally conserved central core but divergent Nand C-terminal domains with additional divergence within its activation loop. Taken together, the nuclear HATs appear to contain a conserved core for Ac-CoA binding but otherwise have different components that fold around this core to facilitate substrate-specific activities.
Catalytic mechanism of nuclear HATs
The structure of the nascent yeast Gcn5 HAT domain, together with mutational and enzymatic studies, reveals that the Gcn5/PCAF HAT enzymes use a ternary complex mechanism (Tanner et al., 1999; Trievel et al., 1999) involving deprotonation of the N-e-nitrogen of the target lysine by a conserved glutamate residue (E173 in yeast Gcn5) within the core domain followed by direct nucleophilic attack of the deprotonated nitrogen on the acetyl group of the Ac-CoA bound cofactor (Figures 1c  and d) . Initial structural studies on the yeast Esa1 HAT domain, together with mutational and in vitro and in vivo studies, revealed that a glutamate residue (E338 in yeast Esa1) that showed structural alignment with the corresponding catalytic glutamate residue of Gcn5/ PCAF played a similar catalytic role. Based on this observation, it was hypothesized that the Gcn5/PCAF and MYST proteins employ similar catalytic mechanisms for catalysis. Subsequent structural, biochemical, mutational and enzymatic studies revealed that the recombinant yeast Esa1 HAT domain employed an active site cysteine (C304 in yeast Esa1) residue to mediate a ping-pong catalytic mechanism (Yan et al., 2002) , involving an acetyl-cysteine intermediate ( Figures  1c and d) . This conclusion was supported by the ability to trap a crystal structure of a C304 acetylated Esa1 intermediate, to biochemically use this intermediate to transfer the acetyl group to target lysine and to demonstrate that both the E338Q and C304A or C304S showed background levels of HAT activity. Interestingly, a very recent report (Berndsen et al., 2007) presents kinetic data that are consistent with a foursubunit piccolo NuA4 complex, containing the Esa1 catalytic HAT subunit, proceeding through a ternary complex mechanism involving E338. The authors further show that a C304A and C304S mutations in Esa1 decreased the k cat by only about 2-and 10-fold, respectively, leading the authors to conclude that the Esa1 containing piccolo NuA4 complex proceeds through a ternary complex mechanism that does not involve a C304 intermediate. These new results imply an apparent discrepancy that will require further analysis, although it is possible that within different contexts (with different proteins or substrates) different mechanisms might be employed by the same enzyme. It is worth noting that several members of the Gcn5/PCAF members contain a cysteine residue in the position corresponding to C304 of Esa1, but these are not mutationally sensitive and the cysteine is not strictly conserved within the Gcn5/PCAF family, as it is in the MYST family. Perhaps, the MYST proteins evolved to retain this cysteine for specialized catalytic purposes.
Although not yet fully characterized, the p300/CBP proteins appear to employ a catalytic mechanism that differs from the Gcn5/PCAF and MYST families of HAT proteins. The observation that the bisubstrate inhibitor Lys-CoA, in which an acetyl bridge is installed between the amine substrate and CoA, is a potent (IC 50 ¼ 500 nM) p300 inhibitor suggested that the enzyme uses a ternary complex mechanism (Sagar et al., 2004) . However, neither the H3-CoA-20 nor H4-CoA-20 peptide-CoA conjugates, where CoA is linked analogously to lysines 14 and 8 of the respective histone peptides, are good p300 inhibitors (with IC 50 values above 10 mM), while the H3-CoA-20 is a potent (IC 50 ¼ 360 nM) PCAF inhibitor (Poux et al., 2002) . Reciprocally, Lys-CoA is not a good PCAF inhibitor (with an IC 50 of 200 mM). These results suggested that p300 might use a ternary complex mechanism that differs from that of the Gcn5/PCAF family of HAT proteins. Interestingly, bisubstrate kinetic analysis of p300 is consistent with a ping-pong catalytic mechanism (Lau et al., 2000a) . More work clearly needs to be performed on characterizing the catalytic mechanism of p300 and a structure of the catalytic domain of p300 or CBP would certainly be of significant use in this regard. Nonetheless, it does appear that the catalytic mechanism of the p300/CBP family differs from that of the Gcn5/ PCAF and MYST families of HAT proteins. Indeed, it is quite surprising that these diverse HAT families may employ different catalytic mechanisms that might reflect the distinct biology that these HAT families are associated with. As described above, it has already been demonstrated that the different catalytic mechanisms between p300 and PCAF can be exploited to develop HAT-specific inhibitors .
Structural basis for HAT inactivation
The only direct structural insights into small moleculemediated inhibition of HAT proteins has come from a crystal structure of the Tetrahymena Gcn5 (tGcn5) HAT domain bound to a modified H3-CoA-20 inhibitor (Poux et al., 2002) described above (Figure 2a) . The bisubstrate inhibitor used in this study was prepared with an isopropionyl bridge between CoA and peptide to more closely mimic the Ac-CoA-lysine intermediate (Lau et al., 2000b) . With an IC 50 of 300 nM for tGCN5, this is the most potent inhibitor to the Gcn5/PCAF family of HATs identified to date. A superposition of the inhibited complex with the ternary tGcn5/CoA/H3 peptide complex shows that although the CoA and lysine substrate superimpose well, the rest of the peptide residues go in different directions and all but four of the residues that flank the lysine substrate are disordered in the inhibited complex. This result suggests that the inhibitor complex represents a late intermediate of the reaction just before peptide release.
Analysis of the tGcn5/inhibitor interface reveals that the pantetheine arm and pyrophosphate of CoA mediate the most extensive protein contacts (Figure 2b ), consistent with the CoA contacts in several other CoAutilizing GNAT enzymes (Clements et al., 1999; Clements and Marmorstein, 2003) . These interactions likely provide a large degree of binding energy, but would be expected to exhibit a low degree of enzyme specificity. The lysine side chain and the isopropionyl linker of the inhibitor also make extensive van der Waals interactions with the protein, but the peptide region of the inhibitor only makes a handful of interactions with the protein. Together, the structure of the tGCN5/H3-(Me)CoA-20 complex reveals that small molecule compounds that optimize the interactions in the CoA pantetheine arm and pyrophosphate, and the lysine and acetyl region, combined with enhanced interactions at the peptide-protein surface, would provide a reasonable starting point for elaborating analogs of H3-(Me)CoA-20 with enhanced Gcn5/ PCAF HAT specificity and potency.
Although no other structures of HAT/inhibitor complexes have been reported, there have been reports of the identification of other less potent HAT inhibitors. Several natural products have been reported including anacardic acid from cashewnut shell liquid (Varier et al., 2004) , and a polyisoprenylated benzophenone derivative from Garcinia indica fruit rind called Garcinol that inhibits both the HAT activity of p300 and PCAF (Balasubramanyam et al., 2004a) with a mid to low micromolar IC 50 value. In addition, a polyphenolic compound from Curcuma longa rhizome was shown to be a specific inhibitor of p300/CBP HAT activity with an IC 50 B25 mM. Interestingly, this inhibitor was shown to be non-competitive with histone or Ac-CoA (Balasubramanyam et al., 2004b) , indicating that it binds to another site on p300/CBP. Structural studies with these other HAT inhibitors may provide new insights into the design of HAT-specific inhibitors. The fact that the p300/CBP HAT proteins are translocated in a subset of leukemias and act downstream of several signal-transduction pathways suggests that p300/HAT inhibitors may have therapeutic value.
Overview of HDACs
Phylogenic analyses have subdivided HDACs into four families. Class I HDACs are homologous to yeast Rpd3 and include human HDAC1-3 and -8; class II are homologous to yeast Hda1 and are further subdivided into classes IIa (including human HDAC4, -5, -7 and -9) and IIb (HDAC6 and -10) based on domain organization and sequence homology. Class III HDACs are named after yeast Sir2 and are also called sirtuins and include yeast Hst proteins 1-4 and human Sirtuins 1-7, and class IV are related to human HDAC11 (Gregoretti et al., 2004) . Class I, II and IV HDACs share sequence and structural homology within their catalytic domains and they share a related catalytic mechanism that does not require a cofactor but does require a zinc (Zn) metal ion. In contrast, the sirtuins do not share sequence or structural homology with the other HDAC families and use a distinct catalytic mechanism that is dependent on the oxidized form of nicotinamide adenine dinucleotide (NAD þ ) as a cofactor (Frye, 2000; Imai et al., 2000) . HDAC activity is generally correlated with transcriptional repression and/or gene silencing (de Ruijter et al., 2003) , and the importance of the class I and II enzymes as drug targets is illustrated by the fact that the aberrant recruitment of HDACs has been mechanistically linked to malignancies in leukemias and lymphomas. Various small-molecule HDAC inhibitors that have shown antitumor activity in model systems have advanced into clinical trials (Lin et al., 2006; Gallinari et al., 2007) , and SAHA (suberoylanilide hydroxamic acid, vorinostat) was recently shown to inhibit the growth of pancreatic cancer cells (Kumagai et al., 2007) and was recently approved by the Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma. There is also a therapeutic interest in the sirtuins as they have been linked to the correlation between caloric restriction and life span extension in model organisms such as yeast, worms, flies, fish and rodents; in mammals, sirtuin activity has been linked to counteracting age-associated diseases such as type II diabetes, obesity and neurodegenerative disorders (Wood et al., 2004a, b; Kobayashi et al., 2005; Parker et al., 2005; Anekonda and Reddy, 2006; Baur et al., 2006) . The association of sirtuins with aging and diseases is discussed in greater detail in this issue of Oncogene (Saunders and Verdin, 2007) . Interestingly, several HDACs have been shown to target non-histone proteins for deacetylation as well. For example, HDAC6 has been shown to deacetylate a-tubulin (Serrador et al., 2004) , and SIRT1 has been shown to deacetylate the p53 tumor suppressor protein (Luo et al., 2001; Cheng et al., 2003) and the forkhead transcription factor (FOXO) (Brunet et al., 2004) and PPARg (peroxisome proliferator-activated receptor-g) (Picard et al., 2004) transcription factors. Together, the different HDACs appear to have distinct substrate specificities leading to the regulation of different biological activities.
Structural insights into catalysis and inhibitor binding by class I and II HDACs
Several structures have been reported for the class I and II HDACs and they provide important insights into the mechanism of action of these enzymes as well as insights into inhibitor design. The first structure that was reported was for a homologue of the class I HDACs from the hyperthermophilic bacterium Aquifex aeolicus called HDLP (histone deacetylase-like protein), which shares 35.2% identity with human HDAC1 (Finnin et al., 1999) . This structure was determined both alone and bound to two hydroxamic acid inhibitors, TSA (tricostatin A) or SAHA. These structures reveal a conserved deacetylase core domain consisting of an open a/b class of folds and a tubular active site pocket containing the inhibitor and a bound Zn ion at the base (Figure 3a) . The structural features present in the active site of HDLP suggest a mode of catalysis that has features of both metallo-and serine proteases in which the bound Zn atom mediates the nucleophilic attack of a water molecule on the acetylated lysine substrate, resulting in a tetrahedral oxyanion intermediate (Figure 3b ). The carbon-nitrogen bond of the intermediate is then broken, with the nitrogen of the scissile bond primed to accept a proton from an Asp-His charge relay, resulting in the formation of the acetate and lysine products.
Interestingly, a theoretical study suggests modifications to the mechanism proposed by Finnin et al. (1999) (Figure 3b ) that differs from the previous proposal in the native protonation states of the His-Asp charge relay systems and the proposal that the deprotonation of water is a distinct step in the mechanism (Vanommeslaeghe et al., 2005) . In addition, a recent report reveals that several HDACs also harbor esterase activity in addition to aminohydrolase activity, and that the esterase activity involves the same active site but does not require an active site tyrosine (Figure 3b ) that is essential for aminohydrolase activity (Moreth et al., 2007) . Taken together, it is clear that additional studies addressing the catalytic mechanism of the class I/II HDACs are still necessary, as these studies are likely to influence our understanding of class I/II HDAC substrates and the development of improved class I/II HDAC inhibitors.
Following the report of HDLP, two different groups reported on the structure of the class I HDAC, HDAC8, bound to several different inhibitors (Somoza et al., 2004; Vannini et al., 2004) . Not surprisingly, HDAC8 shows a high degree of structural homology with HDLP. However, structural differences in the loops surrounding the active site reveal a more accessible active site for HDAC8; leading to the proposal that HDAC8 might accommodate a variety of different substrates. Another significant difference between the HDLP and HDAC8 structures is the identification of a second monovalent metal binding site (K þ or Na þ ) located near the active site in close proximity (7.0 Å ) to the bound Zn ion. In addition, one of the reported HDAC8 structures shows a third monovalent metal binding site away from the active site. Circular dichroism spectroscopy data suggest that K þ ions are required for the structural stability of HDAC8, and the structure suggests that the K þ ion proximal to the Zn ion also plays a role in catalysis. The high degree of conservation of the monovalent ligands among the HDAC proteins suggest that, in addition to Zn association, association with monovalent ions may be a conserved feature of class I HDAC proteins.
More recently, there was a report of a bacterial class II HDAC homologue FB188 HDAH (histone deacetylase-like amidohydrolase from Bordetella/Alcaligenes strain FB188) bound to the reaction product acetate and hydroxamic acid inhibitors (Nielsen et al., 2005) . Sequence alignment of FB188 HDAH with other class I and II HDACs shows 30-35% sequence identity with the two HDAC domains of the class II human HDAC, HDAC6, and only about 20% identity with the class I HDACs, HDLP and HDAC8. Nonetheless, a structural superposition of FB188 HDAH with HDLP and HDAC8 shows that FB188 HDAH is as similar to the HDLP and HDAC8 as these proteins are to each other, highlighting the high degree of structural homology between the class I and II HDACs (Figure 3c ). In particular, the active site Zn ion and both potassium ions in FB188 HDAH were found at the equivalent positions of the metal ions in the HDAC8 structure, and active site residues are essentially superimposable.
The most significant difference between the three class I and II HDACs maps to the surface potential of the proteins. FB188 HDAH is more acidic than the other two HDACs. HDAC8 shows predominantly basic patches, while HDLP shows an equal distribution of acidic and basic residues on the surface. Interestingly, all the proteins appear to be acidic in the area around the entrance to the active site, although the degree of acidity appears to vary (Figure 3d ). In addition, the overall loop structure of the different HDACs, including the loop structure around the active site, appears to differ as well, although it is not clear to what extent these different loop structures reflect different crystal packing environments. Taken together, although it may be possible to exploit the slight differences in the electrostatic properties and loop structures of the active site entrance of the different HDACs, it would appear that designing HDAC-specific inhibitors for the class I and II HDAC members might be particularly challenging. Although some HDAC-specific inhibitors have been identified, such as tubacin, the mode of HDAC specificity exploited by this inhibitor is unknown (Hideshima et al., 2005) .
Overall structure of sirtuins
The class III HDACs, or sirtuins, named after their homology to the yeast Sir2 protein, do not have sequence or structural homology to the class I, II or IV HDACs and employ a different catalytic mechanism (Sauve et al., 2006) . In addition to the acetyl-lysine substrate, sirtuins require the oxidized form of the cofactor NAD þ , for deacetylase activity (Sauve et al., 2001a; Jackson and Denu, 2002) . These proteins convert NAD þ and acetyl-lysine bearing histone substrates to nicotinamide, deacetylated histone lysine and a novel metabolite, 2 0 -O-acetyl-adenosine diphosphate ribose (OAADPR) (Sauve et al., 2001a; Jackson and Denu, 2002) . The catalytic core domain of sirtuin proteins is conserved from bacteria to human, although unlike bacteria and archaea that typically have one or two sirtuin proteins, multicellular organisms contain multiple sirtuin proteins with variable N-and C-terminal domains flanking the catalytic core. For example, Saccharomyces cerevisiae contain five sirtuin proteins (Sir2 and Hst1-4) while there are seven human homologues (SIRT1-7) (Frye, 2000) . Interestingly, SIRT4 and 6 have been shown to catalyse ADP ribosylation instead of deacetylation (Liszt et al., 2005; . The molecular basis for why the SIRT4 and 6 members of this family carry out related but different chemistry is not known.
The structure of the catalytic core domain from several sirtuin proteins from bacteria, archaea, yeast and human have been determined using X-ray crystallography and reveals an elongated conserved catalytic core containing a structurally conserved Rossmann fold domain characteristic of NAD þ /NADH-binding proteins and a smaller, more structurally variable domain containing a structural Zn ion (Marmorstein, 2004) . A cleft between these two domains forms the binding sites for the NAD þ and acetyl-lysine substrates (Figure 4a ). There is one reported structure of a full-length sirtuin protein, yeast Hst2, and this structure shows a homotrimeric structure that appears to be in an autoinhibited form. In particular, this structure shows that residues N-terminal to the catalytic domain sit within the acetyllysine binding pocket of another protein subunit of the trimer and that a C-terminal helix sits within the NAD þ binding site of the same subunit (Zhao et al., 2004) . To what extent this feature is conserved within other sirtuins is unknown; however, it appears unlikely since regions N-and C-terminal to the conserved catalytic core show no sequence conservation among the sirtuin proteins.
Catalytic mechanism of the sirtuins
Although the reactants b-NAD þ and acetyl-lysine, and products: OAADPR, deacetylated lysine histones and nicotinamide of the sirtuin deacetylation reaction are well established, the detailed chemical mechanism has been a matter of debate in the literature. Nicotinamide has also been shown to be a non-competitive inhibitor of the sirtuin reaction, and the molecular basis for how this occurs has also been a matter of debate. The underlying chemistry of the sirtuin deacetylation reaction as well as the nicotinamide inhibitory reaction has remained an important issue, as it would influence the rational design of small molecule sirtuin effectors. The following aspects of the sirtuin reaction are generally accepted. First, for the deacetylation reaction, the binding of acetyl-lysine is required for nicotinamide hydrolysis and the reaction proceeds through formation of an O-alkylamidate intermediate, involving attack of the acetyl-lysine acetyl group on the 1 0 carbon of the ribose ring (Sauve et al., 2001b; Jackson and Denu, 2002) (Figure 4b ). It is also well accepted that the nicotinamide inhibition reaction occurs by base exchange of nicotinamide with an intermediate of the deacetylation reaction to reform b-NAD þ through a transglycosidation reaction (Jackson et al., 2003; Sauve and Schramm, 2003 ; Figure 4b ).
There are two major issues of debate. This first issue has to do with the mode of nicotinamide hydrolysis. One model argues for an S N 2-like reaction where nicotinamide hydrolysis from the b-face of the C1 0 position of the nicotinamide ribose ring is mechanistically linked to nucleophilic attack on the a-face of the same carbon by the acetyl group of acetyl-lysine forming the O-alkylamidate intermediate (Hoff et al., 2006; Khan and Lewis, 2006; Figure 4b ). This model is supported by a crystal structure of an unreacted ternary complex between a bacterial sirtuin, acetyl-lysine and NAD þ , which shows the acetyl group of acetyl-lysine in position to attack the a-face of the 1 0 carbon of the ribose ring (Hoff et al., 2006) . However, the fact that the reaction has not turned over in the crystals argues that this ternary complex might not represent the catalytically competent substrate configuration. A second model argues for an S N 1-like reaction where nicotinamide hydrolysis occurs first followed by a rotation of the nicotinamide ribose ring to permit acetyl-lysine attack on the a-face of the 1 0 carbon of the nicotinamide ribose ring. This mechanism necessitates formation of an oxocarbenium ion intermediate after hydrolysis of the nicotinamide and before nucleophilic attack of the acetyl group of acetyl-lysine (Figure 4b ). Consistent with this mechanism is a crystal structure of a ternary complex of yHst2 with acetyl-lysine and a non-hydrolysable analogue of NAD þ , carba-NAD þ , in which the in-ring oxygen of the nicotinamide ribose is replaced with a carbon atom (Zhao et al., 2004) . This structure shows that the acetyl group of acetyl-lysine is hydrogen bonded to the 2 0 -and 3 0 -OH groups of the nicotinamide ribose and is not in position to carry out nucleophilic attack at the 1 0 carbon of the nicotinamide ribose ring. Instead, the carbonyl of a conserved asparagine residue, shown to be essential for nicotinamide hydrolysis, is in position to stabilize a positively charged oxocarbenium ion. Also consistent with this mechanism is a structure of a ternary complex with yHst2, acetyl-lysine and the intermediate analogue, ADP-ribose that reveals that the nicotinamide ribose ring rotates about 901 relative to its orientation in carba-NAD þ and now places carbonyl oxygen of acetyl lysine in position to carry out nucleophilic attach on the 1 0 carbon on the a-face of the nicotinamide ribose ring (Zhao et al., 2004) . These differing models for the mode of nicotinamide hydrolysis also have implications for the mode of nicotinamide inhibition.
The mode of nicotinamide inhibition of Sir2 proteins has been a second issue of debate in the literature. One model argues that nicotinamide binds to the same region, or so called 'C-pocket' that binds the nicotinamide group of NAD þ ( shows nicotinamide bound in the C-pocket (Avalos et al., 2005) . However, neither Sir2-Af2/NAD þ , Sir2-Af2/ADP-ribose nor Sir TM/acetyl-lysine is the enzymatic complex to which an inhibitory nicotinamide molecule is expected to bind. A second model argues that the inhibitory nicotinamide molecule binds to a nearby 'D-pocket' that is distinct from the C-pocket (Figure 4c ). This model was initially based on a structure of yHst2 in complex with lysine-16 histone H4 and a reaction intermediate analogue, ADP-ribose, that modeled an incoming nicotinamide molecule within the D-pocket (Zhao et al., 2004) . More recently, a crystal structure of nicotinamide within the D-pocket was obtained by socking nicotinamide into crystals containing yHst2, lysine-16 histone H4 and reaction intermediate analogue designed to mimic the oxocarbenium ion, ADP-HPD (Sanders et al., 2007) . In addition, biochemical studies showed that mutagenesis of the residues in the D-pocket does not significantly affect NAD þ binding while having more significant effects on the K i for nicotinamide inhibition. This same study revealed that a mutation in the C-pocket of an asparagine residue that contacts nicotinamide in NAD þ decreases NAD þ binding but does not alter the K i for nicotinamide inhibition. Based on these results, it appears that the D-pocket plays a more significant role for nicotinamide inhibition and base exchange by the sirtuin proteins, although additional experiments will likely have to be carried out to resolve this discrepancy.
Sirtuin effectors
The liganded sirtuin structures described above point to the targeting of either the acetyl-lysine or NAD þ binding site for protein inhibition. However, since many other NAD þ utilizing enzymes use a structurally conserved Rossmann fold to bind NAD þ , targeting the NAD þ site might not be sufficiently specific for the sirtuin proteins. The acetyl-lysine target site is, however, a viable option for the design of sirtuin inhibitors, particularly since the acetyl-lysine binding site shows significant differences with the acetyl-lysine binding site of the class I/II HDACs. Consistent with targeting the acetyl-lysine site of the sirtuin proteins for inhibition, a recent report describes the identification of the sirtuin inhibitor cambinol that shows competitive binding with acetyl-lysine (Heltweg et al., 2006) . The targeting of the nicotinamide inhibitory, D-pocket, may also represent a fruitful avenue of investigation. Since nicotinamide is a known physiological regulator of sirtuin enzymes, relief of nicotinamide inhibition would be expected to result in the net activation of sirtuin proteins. Molecules that block the D-pocket and the nearby C-pocket may also serve as potent and specific Sir2 inhibitors.
To date, several sirtuin effectors have been described including the inhibitors, sertinol (Kiviranta et al., 2006) , splitomicin (Posakony et al., 2004) and a group of indole analogues and the activator resveratrol (Biel et al., 2005) . The resveratrol activator has received much attention because of its many reported health benefits including its use as a chemotherapeutic agent (Manson et al., 2005) . Interestingly, although cell-based studies have clearly shown a SIRT1-dependant activation in response to resveratrol (Howitz et al., 2003; Wood et al., 2004a; Baur et al., 2006) , the biochemical activation of sirtuin proteins has been a matter of debate and will require further study (Howitz et al., 2003; Borra et al., 2005; Kaeberlein et al., 2005) . The structural basis for how resveratrol or the other identified effectors of the sirtuin enzymes work is still unclear and will require structural characterization of relevant sirtuin/effector complexes.
Perspectives
This review illustrates the complexity, structural diversity and mechanistic ingenuity of the enzymes that catalyse acetyl-transfer on histones. We now have structures and the enzymatic characterization of several of the protein subfamilies that mediate this acetyl transfer. Together, this has provided a wealth of information on the chemistry of these enzymes that can now be exploited to design small molecule compounds that might effect the activity of these enzymes in ways that may be useful for the treatment of human disease and cancer in particular. Despite these efforts, however, there are still unresolved issues and more recent accumulating data that suggest that there is still much work ahead.
With regard to the HAT enzymes, do the different subfamilies use a conserved ternary complex catalytic mechanism or do they use different catalytic mechanisms that are perhaps modulated in a substrate specific way? How different is the structure of the p300/CBP HAT from the Gcn5/PCAF and MYST HATs and what is the relationship of their catalytic mechanisms? Resolving issues such as these may be at the heart of designing HAT-specific inhibitors that may be used for targeting, for example, chromosomal translocations in leukemia that involve the p300/CBP and MYST family of HAT proteins.
With regard to the class I and II HDACs, although vorinostat has been approved by FDA for treating T-celllymphoma treatment, it will be interesting to follow the development of other class I/II HDAC inhibitors in current clinical trials to determine if these general inhibitors will be useful or if more specific class I/II HDAC inhibitors need to be developed. If the latter is the case, it will be helpful to obtain more structural information of other class I/II HDACs, where HDAC1 and -2 appear to be at the top of the wish list. Additional enzymatic studies will also be required to resolve some of the disparities underlying the catalytic mechanism and substrates of the class I/II HDACs, as resolving such issues are likely to contribute to the further development of class I/II HDAC inhibitors. There is a strong case to be made for the development of sirtuin effectors for the treatment of age-associated diseases such as type II diabetes, obesity, neurodegenerative disorders and cancer. Structural information of sirtuin proteins bound to effectors may be useful for structure-based design efforts and it would appear that targeting of the nicotinamide inhibitory C-or D-pockets for the development of both sirtuin activators and inhibitors might be particularly fruitful for the development of broad-based sirtuin effectors. It is unclear at this point if sirtuin-specific effectors will be desirable, but if this is the case, additional structures of the various homologues may be useful. Although there are still a lot of questions that remain underlying the chemistry and small molecule regulation of these fascinating enzymes that mediate acetyl transfer, one thing remains clear -the acetylation status of histones represents an important signal-transduction pathway that is critical for normal cell processes and will remain an important target for the treatment of human diseases such as cancer.
Notes added in proof
During the revision of this review three relevant manuscripts were published: (1) Nielsen et al. (2007) reported on the structure of a bacterial class II HDAC bound to a trifluromethylketone inhibitor revealing the first structure of an HDAC bound to a non-hydroxamate HDAC inhibitor; (2) Schuetz et al. (2007) reported on the structure of SIRT5 bound to the inhibitor suramin revealing the first structure of a sirtuin/inhibitor complex; and (3) Smith and Denu (2007) reported on a study demonstrating nucleophilic participation of acetyl-lysine in NAD þ cleavage, supporting an S N 2-like catalytic mechanism for Sir2 proteins.
